Screener
Cytokinetics CYTK Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $20,510 | $22,337 |
| Accrued liabilities | 76,862 | 83,278 |
| Short-term operating lease liabilities | 21,042 | 19,111 |
| Current portion of convertible and long-term debt | 27,358 | 41,181 |
| Derivative liabilities measured at fair value | 30,700 | 31,100 |
| Deferred revenue | 1,653 | 1,612 |
| Other current liabilities | 3,304 | 3,833 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's operating lease liabilities (current)?
- Cytokinetics (CYTK) reported operating lease liabilities (current) of $21.04M in Q2 2026.
- How has Cytokinetics's operating lease liabilities (current) changed year-over-year?
- Cytokinetics's operating lease liabilities (current) increased by 7.4% year-over-year, from $19.59M to $21.04M.
- What is the long-term trend for Cytokinetics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Cytokinetics's operating lease liabilities (current) has grown at a 47.0% compound annual growth rate (CAGR), from $2.79M to $19.11M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Cytokinetics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude